Alex Lyakhovichhttps://www.etis.ee/CV/Alex Lyakhovich/est
Teaduspreemiad ja tunnustused
2010, Alex Lyakhovich, 2010 Best scientific award (Minneapolis) from Fanconi Anemia Research Foundation
2002, Alex Lyakhovich, 2002 Pharmacia Award at AACR (San Francisco) for Scientific Merit
since 2010 appointed as a Faculty and Asst. Prof. (cancer biology) at Duke University/Duke NUS Graduate Medical School
Alex Lyakhovichhttps://www.etis.ee/CV/Alex Lyakhovich/eng
My professional work has been centered around cancer biology issues concerning development and progression of breast, prostate and colorectal cancers from several different angles. Soon after my doctoral training in Germany, I moved to the Michigan Cancer Foundation (MCF) where I worked on the postreplication repair protein Rad6. I then moved to the Universitat Autonoma de Barcelona, where I studied Fanconi Anemia (FA) disease and cancer predisposition. Again, my work in Barcelona was about cancer-proneness, particularly the role of the FA genes in this process. Among other interesting findings was the role of FA and other DDR-related diseases in oxidative stress. This part, done both in UAB, Barcelona and in Vienna, allowed me to identify a couple of dozen deregulated genes and proteins, half of which turned out to be associated with mitochondria. In between my work at UAB and MCF, I was able to do some training in molecular biological and biochemical techniques, splitting my fellowship between the University of Michigan Ann Arbor and Rutgers University Medical School. Next, I worked at Duke-NUS, Singapore in a rank of Assistant Professor where I developed my own research line focusing on mitochondrial dysfunction in pathological conditions. I continued working on mitochondria in newly established European center in Brno (awarded start-up FP7 grant and group leader position, declined) and as a Marie Curie Senior Fellow in Barcelona where I became principal investigator. My current research is aimed at understanding the roles of mitochondria in proliferation and regulation of cancer resistance. The second part of my work deals with cancer stem cells, the role of metabolic processes in connection to metastasis and finding novel strategies to eliminate this subset of cells.